R or SNU387 R cells were transiently transfected with the indicated siRNA (each at 10 nM). At 48 h after transfection, cell lysates were subjected to Western blot analysis. (C) Malme3M R cells were transiently transfected with the indicated siRNA (each at 10 nM). The next day, cells were then treated with taxol (1 μM) for 24 h, followed by Western blot analysis. (D) The indicated cancer cells were transiently transfected with the indicated siRNA (each at 10 nM). The next day, cells were then treated with various concentrations of taxol for 24 h, followed by MTT assays. The mean ± S.E. of three independent experiments is shown. **p < 0.005. (E) Cell lysates from the indicated cancer cells were immunoprecipitated with the indicated antibody (2 μg/ml), followed by Western blot analysis. (F) Immunofluorescence staining employing the indicated antibody was performed. DAPI staining was also performed to determine the integrity of the indicated cancer cells.
The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3β and decreasing the expression of cyclinD1
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Supplementary Figure 1: CAGE increases the expression of cyclin D1 and pGSK3β
Ser9 while decreasing the expression of phospho-cyclinD1
Thr286
. (A) Cell lysates isolated from the indicated cancer cell lines were subjected to Western blot analysis.
(B) Immunofluorescence staining employing the indicated antibody was performed. (C) Malme3M cells were transfected with control vector (1 μg) or CAGE (1 μg). At 48 h after transfection, cell lysates were subjected to Western blot analysis (left panel). Malme3M
R cells were transfected with the indicated siRNA (10 nM). At 48 h after transfection, cell lysates were subjected to Western blot analysis (right panel). (D) Malme3M R cells were transfected with the indicated siRNA (10 nM). At 48 h after transfection, immunofluorescence staining employing the indicated antibody was performed.
Supplementary Figure 4: Full-length CAGE mutants (G-T-G-A-T and G-T-G-K-A) do not confer resistance to anticancer drugs. (A)
Malme3M cells were transfected with the indicated with the construct (each at 1 μg). The next day, cells were then treated with various concentrations of celastrol or taxol for 24 h, followed by MTT assays. The next day, cells were then treated without or with GTGKT peptide (10 μM) along with taxol (1 μM). At 24 h after treatment, Western blot analysis was performed.
